Title Image

PROGRAM

Hours are depicted in Central European Time (CET)

Thursday July 1st 2021

12.00-12.30Welcome: Christina Kanaka- Gantenbein, Greece, Vana Spoulou, Greece and Johannes Liese, Germany
12.30-14.30Workshop 1: What is the burden of Varicella disease in Countries without or before universal varicella vaccination (UVV)
Chairs: Vana Spoulou, Greece, Sophie Alain, France
Speakers:
Sophie Alain
, France
Marion Roderick
, UK
Oana – Falup Pecurariu
, Romania
Vytautas Usonis
, Lithuania
Alies van Lier
, The Netherlands
Adamos Hadjipanayis, Cyprus
Anita Heywood
, Australia
15’ Discussion
14.30-15.00Break
15.00-17:30Workshop 2: What is the burden of Varicella disease in countries after introduction of UVV
Chairs: Johannes Liese, Germany, Mona Marin, USA
Speakers:
Mona Marin, USA
Anette Siedler, Germany
Timo Vesikari, Finland
Vana Papaevangelou, Greece
Giovanni Gabutti, Italy
Manuel Garcia Cenoz, Spain
Guillermo Barrenechea, Argentina
Cheng-Hsun Chiu, Taipei
20’ Discussion: Overview of the global experience with UVV
17:30-18:00Lecture 1
Chair: George Chrousos, Greece, Maria Tsolia, Greece
The global varicella burden from the past to the future
Ann Gershon
, USA

 


 

Friday July 2nd 2021

11.00 -12.15Workshop 3: VZV virology: How advances in molecular biology helps our understanding on the pathogenesis of VZV
Chairs: George Sourvinos, Greece, Judith Breuer, UK
Modulation of T cell migration and adhesion by VZV – A novel strategy to facilitate virus spread?
Abel Viejo Borbolla
, Germany
Molecular epidemiology of VZV and vOKA strains (The Origin and Migration of Varicella Zoster Virus Strains)
Judith Breuer
, UK
VZV- associated disease beyond Varicella and HZ
Michael Gershon
, USΑ
15’ Discussion
12.15-12.30Break
12.30-13.15Lectures: Safety of Varicella vaccines
Safety of Varicella OKA/MSD vaccine. 22 years of experience
Meredith Woodward, USA
Safety of GSK-Oka vaccines: evidence and risk-management
Giacomo Casabona,
Belgium
13.15- 14:00Workshop 4: VZV vaccines in patients with immunocompromised and other chronic conditions
Chairs: Susanna Esposito Italy, Timo Vesikari, Finland
Burden and complications of varicella in patients with immunocompromised and chronic conditions
Johannes Liese, Germany
VZV vaccines safety and efficacy in patients with immunocompromised and chronic conditions, including pregnancy
Susanna Esposito
, Italy
15’ Discussion
14.00-14.30Break
14.30-15.30Workshop 5: What are the most important barriers associated with vaccination coverage of varicella vaccine?
Chairs: Paolo Bonanni, Italy, Maria Theodoridou, Greece
Role of Scientific Societies and of Recommending Authorities
Paolo Bonanni, Italy
Role of physicians
Manolis Galanakis
, Greece
20’ Discussion
15: 30-16.30Workshop 6: Viral vs host interactions in VZV infection
Chairs: Ann Gershon, USA, Vana Spoulou, Greece
Stem cell-derived human neurons to study VZV latency and reactivation
Tomohiko Sadaoka, Japan
Immune responses to VZV and vOKA strain and correlates of protection
Vana Spoulou, Greece
15’ Discussion
16.30-16.45Break
16:45-18:15Workshop 7: Can we predict the effects of UVV on Varicella and HZ?
Chair: Paolo Bonanni, Italy,
Effect of Routine Varicella Vaccination on Herpes Zoster Incidence
Raphael Harpaz, USA
Endogenous and exogenous boosting: Modeling vs. real world
Vana Papaevengelou
, Greece
Validity of mathematic models used for decision to introduce UVV
Johannes Horn
, Germany
15’ Discussion
18:15-18:30Lecture
Chair: Michael Oxman, USA
From varicella to Zoster Vaccines
Timo Vesikari, Finland

 


 

Saturday July 3rd 2021

10.00-10.30HZ vaccines (GSK, Merck)
Chair: Timo Vesikari, Finland
The recombinant zoster vaccine: a review of key clinical data
Speakers:
Nicolas Lecrenier, Belgium
15’ Discussion
10.30-12.00Workshop 8: What is the burden of herpes zoster (HZ) in adults and how it can be reduced by currently available HZ vaccines?
Chair: Timo Vesikari, Finland
The burden of the herper zoster in adults
TBA
Efficacy and safety of licensed HZ vaccines: in special patient groups
Elderly

Michael Oxman
, USA
Recommendations and implementation and acceptance of vaccination against HZ in Germany
Anette Siedler,
Germany
15’ Discussion
12.00-12.15Break
12.15-13.20Workshop 9: How far can the burden of varicella and HZ be reduced
Chair: Carlo Giaquinto, Italy
Cost effectiveness of UVV and Herpes Zoster vaccination programs
Alies van Lier
, The Netherlands
Modelling the impact of combined vaccination programs against VZ and HZ
Valentina Marziano, Italy
What is the best way to implement varicella and HZ immunization? The review of current evidence”
David Greenberg, Israel
13:20-14:00Panel Discussion
Implementing UVV and HZ: Barriers to overcome and the way to move forward
Vana Spoulou, Johannes Liese, Ann Gershon, Carlo Giaquinto
Symposium Closing